What are the Implications of SWOG S1826 for Treating Classical Hodgkin's Lymphoma?

In this episode, hosts Ronak Mistry, DO; Vivek Patel, MD; and Dan Hausrath, MD, are joined by the hosts of Two Onc Docs.

They discuss how classical Hodgkin’s lymphoma is currently treated and discuss the implications of data from SWOG S1826. Alex Herrera, MD, presented results from the randomized study during a plenary session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

The randomized study compared nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD) with brentuximab vedotin plus AVD in advanced stage classic Hodgkin lymphoma.

The SWOG S1826 results presented at ASCO showed nivolumab plus AVD improved progression-free survival over brentuximab vedotin plus AVD.